← FDA DRUG APPROVALS

FDA ANDA · ANDA209824

VIGABATRIN

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA209824
TYPE
ANDA
ORIGINAL APPROVAL
2018-04-23
LATEST ACTION
2026-03-18
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Discontinued

Products

VIGABATRINDiscontinued
VIGABATRIN 500MG/PACKET · FOR SOLUTION · ORAL

Approval history

2026-03-18REMS · Supplement 15AP
2024-09-12REMS · Supplement 13AP
2022-10-27Labeling · Supplement 10 · standardAP
2022-10-12REMS · Supplement 11AP
2020-10-02REMS · Supplement 9AP
2020-08-03Labeling · Supplement 1 · standardAP
2020-08-03Labeling · Supplement 6 · standardAP
2020-04-17REMS · Supplement 8AP
2019-09-12REMS · Supplement 5AP
2019-05-30REMS · Supplement 2AP
2018-04-23UNKNOWN · Original · standardREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →